Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

758
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
758
Cancer Vaccines01:30

Cancer Vaccines

860
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
860
Subviral Agents01:29

Subviral Agents

359
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
359
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

6.7K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-driven neoantigen identification: a comprehensive review from somatic variant calling to T cell recognition.

Journal of translational medicine·2026
Same author

Designing a novel therapeutic candidate vaccine for HPV16 using immunoinformatics approach: Targeting E6 and E7 epitopes with TLR4 agonist integration.

BioImpacts : BI·2026
Same author

Retraction notice to 'Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology' [Environ. Res. 239 (2023) 117263].

Environmental research·2026
Same author

PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets.

Research in pharmaceutical sciences·2026
Same author

The rotavirus cVLP<sub>VP8∗</sub> vaccine candidate induces cross-genotype/heterotypic neutralizing antibody responses against human rotavirus G9P[4].

Virology·2026
Same author

Comparative molecular dynamics mapping of metallocarboxypeptidase-peptide interfaces reveals potential hotspots that inspire novel inhibitor design.

Scientific reports·2026

Related Experiment Video

Updated: Dec 11, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Oncolytic virotherapy: Challenges and solutions.

Nasser Hashemi Goradel1, Alexander T Baker2, Arash Arashkia3

  • 1Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

Current Problems in Cancer
|August 24, 2020
PubMed
Summary
This summary is machine-generated.

Oncolytic virotherapy uses viruses to target cancer cells, a field with historical roots. Overcoming challenges like immune response and tumor penetration is key for advancing this promising cancer treatment.

Keywords:
BiomarkersCancerOncolytic virotherapyTumor microenvironment

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.3K

Related Experiment Videos

Last Updated: Dec 11, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.3K

Area of Science:

  • Oncolytic virology
  • Cancer therapy
  • Virology

Background:

  • Viruses have been explored as cancer therapies since the 19th century.
  • The field of oncolytic virology emerged from observations of viruses selectively destroying cancer cells.
  • Oncolytic virotherapy offers a promising avenue for cancer treatment.

Purpose of the Study:

  • To discuss various types of oncolytic viruses.
  • To review the application of oncolytic viruses in clinical trials.
  • To identify challenges in oncolytic virotherapy and propose strategies to overcome them.

Main Methods:

  • Literature review of oncolytic virotherapy.
  • Analysis of clinical trial applications of oncolytic viruses.
  • Discussion of challenges and potential solutions in the field.

Main Results:

  • Oncolytic viruses demonstrate selective lysis of cancer cells.
  • The first FDA-approved oncolytic virus, talimogene laherparepvec (T-VEC), was approved in 2015.
  • Significant progress has been made, but challenges persist.

Conclusions:

  • Oncolytic virotherapy is a developing field with potential against cancer.
  • Key challenges include tumor penetration, immune response, and biomarker development.
  • Continued research is essential to overcome hurdles and enhance therapeutic efficacy.